Following a landmark 2009, during which Lifeline recorded its first full-year operating profit, the Company has experienced steady growth during 2010. Revenue for the first half is expected to be at least in line with current market expectations while operating profit is expected to be significantly ahead of last year’s maiden interim operating profit.
The Company expects to announce interim results in September.
Enquiries
Lifeline Scientific, Inc. + 1 847 294 0300 David Kravitz, CEO Seymour Pierce (Nomad) +44 (0)20 7107 8000 Mark Percy Financial Dynamics +44 (0)20 7831 3113 Ben Brewerton / John Dineen
About the LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, the Company’s lead product, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a physiologic solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is being preserved outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant.
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based medical technology company with European headquarters located in Brussels. Serving leading transplant programs in 15 countries, it is the largest company in the world dedicated exclusively to addressing unmet medical needs in pre-transplant organ preservation, transport, evaluation and therapy. Its primary commercial focus is the global launch of its FDA cleared, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. LifePort based product line extensions for preservation of the liver, pancreas and other organs are in development.
